Mark Emalfarb

Mr
Mark
Emalfarb

CEO
Dyadic International Inc
Email 
memalfarb [at] dyadic.com
Biography

Founder & CEO of Dyadic International (Nasdaq:DYAI)

Developed the C1 protein production platform a rapid more efficient recombinant protein manufacturing process that can be used at flexible commercial scales. 

 

Animal and Human vaccines and antibodies 

https://www.dyadic.com/media-center/scientific-publications/

Research interests

To help speed the development and lower the cost of manufacturing recombinant protein vaccines and antibodies 

https://www.dyadic.com/media-center/scientific-publications/

 

Discipline
Bio-manufacturing Cellular biology Systems biology
Host species
Cats Cattle Dogs Fish Horses Pigs Poultry Small ruminants Zoonoses
Pathogen
Viruses Viruses›African swine fever virus Viruses›Bovine ephemeral fever virus Viruses›Classical swine fever virus Viruses›Coronavirus Viruses›Ebolaviruses/filoviruses Viruses›Foot-and-mouth disease virus Viruses›Influenza virus Viruses›Mareks disease virus Viruses›Newcastle disease virus Viruses›Nipah virus Viruses›Poxviruses Viruses›Rabies virus Viruses›Retroviruses Viruses›Rift Valley fever virus Viruses›Rotavirus
Stage of vaccine development
Adjuvants Antigen discovery and immunogen design Clinical trials Commercialisation Pre-clinical trials Vaccine delivery